BridgeMD
New treatment option for Solid Tumors
Official title A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06710379
What this study is testing
What is ADRX-0405?
ADRX-0405 is an investigational medicine, being studied as a potential treatment for solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Phase 1a Dose Escalation: people with histologically confirmed select advanced solid tumors, including metastatic castration resistant prostate...
- Phase 1b Dose Expansion: people with histologically confirmed prostate adenocarcinoma that is confirmed to be castration resistant (i.e., serum...
- Measurable disease according to RECIST version 1.1 or evaluable disease per PCWG3 for people with prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 in 1a; 0-2 in 1b
- Adequate hematologic, liver, and renal function
You likely can't join if
- Active and uncontrolled central nervous system metastases
- Significant cardiovascular disease
- History of another malignancy other than the one for which the subject is being treated on this study within 3 years
- Receipt of any anticancer or investigational therapy within: 5 elimination half-lives or 14 days (whichever is less); 4 weeks for any therapeutic...
- History of (non-infectious) ILD/pneumonitis that required steroids within 2 years of study enrollment, has current ILD/pneumonitis, or where...
- Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted
The study team makes the final eligibility decision.
Where it's taking place
- Duarte, California, United States
- Santa Monica, California, United States
- Grand Rapids, Michigan, United States
- Minneapolis, Minnesota, United States
- Austin, Texas, United States
- Houston, Texas, United States
- West Valley City, Utah, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Duarte, California, United States; Santa Monica, California, United States; Grand Rapids, Michigan, United States; Minneapolis, Minnesota, United States; Austin, Texas, United States; Houston, Texas, United States and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.